Congress is starting to get some answers on EpiPen pricing. And though, so far, Mylan’s not offering much beyond what’s readily available via Google search,…

The EU’s pushback on pay-for-delay arrangements among drugmakers is being tested today as its top court considers appeals from half a dozen drugmakers fined…

Three strikes for the patents on Teva’s long-acting Copaxone formula, but the branded drug isn’t out of the exclusivity game yet.


The University of Minnesota wants a piece of Gilead’s hep C business. The school sued for patent infringement Monday, seeking royalties on the drugs’…

If Mylan was hoping that its new EpiPen copay assistance and authorized generic would stave off government probing, then it’s hoping in vain. Another…

The Attorney General of New Hampshire is accusing Purdue Pharma of dragging its feet in his investigation into Purdue’s marketing of its highly addictive…

After a former Insys Therapeutics sales rep admitted she had paid kickbacks to doctors to prescribe the company's sprayed cancer pain opioid fentanyl for…

A California whistleblower case against Celgene has moved forward with the unsealing of thousands of pages of new documents that attorneys for a former sales…